Castle Biosciences, Inc. CSTL
$35.17
$1.735.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -145.54% | 43.82% | -124.32% | -122.08% | -49.29% |
| Total Depreciation and Amortization | -82.69% | -59.34% | -34.52% | -559.87% | 602.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 176.68% | -74.38% | 63.97% | 66.62% | -260.18% |
| Change in Net Operating Assets | -86.70% | 5.02% | 604.44% | 1,382.35% | 345.08% |
| Cash from Operations | -26.99% | -266.62% | 10.53% | -3.03% | -13.24% |
| Capital Expenditure | 6.62% | -162.76% | 5.06% | -132.58% | -77.15% |
| Sale of Property, Plant, and Equipment | -50.00% | -22.22% | -28.57% | 375.00% | 500.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,725.19% | 24.55% | 20.11% | 57.53% | 97.52% |
| Cash from Investing | 43.75% | -15.03% | 53.05% | -24.34% | -32.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 22.58% | 7.69% | -3.85% | -29.17% | -181.82% |
| Issuance of Common Stock | 75.33% | 60.83% | 175.10% | -86.22% | -20.51% |
| Repurchase of Common Stock | -34.63% | -162.35% | -15.50% | 8.42% | 4.23% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -626.32% | -- | -- | -- | -- |
| Cash from Financing | -977.23% | -224.08% | 14.78% | -209.67% | 140.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.90% | -76.43% | 25.95% | -64.60% | -384.25% |